Other
Celecoxib
0
Pipeline Programs↗
2
Active Trials↗
3
Companies Involved↗
Celecoxib is an early-stage landscape with 0 programs across 3 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Akebia Therapeutics, Novartis.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
37
clinical trials
Completed28 · 76%
Withdrawn3 · 8%
Unknown status3 · 8%
Recruiting1 · 3%
Not yet recruiting1 · 3%
Suspended1 · 3%
Clinical Trials
Trial Activity
37 trials
CELECOXIB Plasma and Cerebral Spinal Fluid Pharmacokinetics in Children
Recruiting·—·Phase 2·NCT01344200·65 enrolled
Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00139776·875 enrolled
A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer
Completed·—·Phase 2·NCT00165451·20 enrolled
A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 1·NCT00813241·16 enrolled
Study of Celecoxib Bioavailability in Healthy Subjects
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 1·NCT00296127·24 enrolled
Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00640809·408 enrolled
GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00373685·8,067 enrolled
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
Completed·—·Phase 2·NCT00357500·101 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)